Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

被引：29

作者：

Li, Chia-Jung ^{[1
,2
]}

Tzeng, Yen-Dun Tony ^{[3
,4
]}

Chiu, Yi-Han ^{[5
]}

Lin, Hung-Yu ^{[6
]}

Hou, Ming-Feng ^{[7
]}

Chu, Pei-Yi ^{[8
,9
,10
,11
]}

机构：

[1] Kaohsiung Vet Gen Hosp, Dept Obstet & Gynecol, Kaohsiung 813, Taiwan

[2] Natl Sun Yat Sen Univ, Inst BioPharmaceut Sci, Kaohsiung 804, Taiwan

[3] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung 813, Taiwan

[4] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan

[5] Soochow Univ, Dept Microbiol, Taipei 111, Taiwan

[6] Show Chwan Mem Hosp, Res Assistant Ctr, Changhua 500, Taiwan

[7] Kaohsiung Med Univ, Dept Surg, Chung Ho Mem Hosp, Ctr Canc Res,Div Breast Surg, Kaohsiung 807, Taiwan

[8] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei 242, Taiwan

[9] Show Chwan Mem Hosp, Dept Pathol, Changhua 500, Taiwan

[10] Chung Chou Univ Sci & Technol, Dept Hlth Food, Changhua 510, Taiwan

[11] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 704, Taiwan

来源：

CANCERS | 2021年 / 13卷 / 12期

关键词：

breast cancer; target therapy; biomarkers; pathogenesis; GROWTH-FACTOR RECEPTOR; INDEPENDENT PROGNOSTIC MARKER; TYROSINE KINASE INHIBITOR; ALDEHYDE DEHYDROGENASE 1; TUMOR-SUPPRESSOR GENE; RANDOMIZED PHASE-II; ESTROGEN-RECEPTOR; NEOADJUVANT CHEMOTHERAPY; PROGESTERONE-RECEPTOR; PREDICTIVE BIOMARKERS;

D O I：

10.3390/cancers13122978

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Breast cancer emergencies have become a rapidly evolving field in medicine during the last ten years. Carcinogenesis is a multiparametric process that involves diverse factors such as genetic, environmental, or aging. Recent research that elucidates the tumor biology and molecular pathways that mediate cancer progression and drug resistance has led to the development of various molecular targeted therapies involving monoclonal antibodies, small molecule receptor tyrosine kinase inhibitors, and agents that block downstream signaling pathways in breast cancer. Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.

引用

页数：21

共 140 条

[1] Triple Negative Breast Cancer: A Tale of Two Decades [J].

Ali, Arwa M. ;

Ansari, Jawaher A. K. ;

Abd El-Aziz, Nashwa M. ;

Abozeed, Waleed N. ;

Warith, Ahmed M. Abdel ;

Alsaleh, Khalid ;

Nabholtz, Jean-Marc .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (04) :491-499

[2] Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer [J].

Arima, Yoshimi ;

Hayashi, Naoki ;

Hayashi, Hidemi ;

Sasaki, Mikako ;

Kai, Kazuharu ;

Sugihara, Eiji ;

Abe, Eriko ;

Yoshida, Atsushi ;

Mikami, Shuji ;

Nakamura, Seigo ;

Saya, Hideyuki .

INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (11) :2568-2579

[3] Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial [J].

Bartlett, John M. S. ;

Brookes, Cassandra L. ;

Robson, Tammy ;

van de Velde, Cornelis J. H. ;

Billingham, Lucinda J. ;

Campbell, Fiona M. ;

Grant, Margaret ;

Hasenburg, Annette ;

Hille, Elysee T. M. ;

Kay, Charlene ;

Kieback, Dirk G. ;

Putter, Hein ;

Markopoulos, Christos ;

Kranenbarg, Elma Meershoek-Klein ;

Mallon, Elizabeth A. ;

Dirix, Luc ;

Seynaeve, Caroline ;

Rea, Daniel .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :1531-1538

[4] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer [J].

Baselga, Jose ;

Gomez, Patricia ;

Greil, Richard ;

Braga, Sofia ;

Climent, Miguel A. ;

Wardley, Andrew M. ;

Kaufman, Bella ;

Stemmer, Salomon M. ;

Pego, Antonio ;

Chan, Arlene ;

Goeminne, Jean-Charles ;

Graas, Marie-Pascale ;

Kennedy, M. John ;

Ciruelos Gil, Eva Maria ;

Schneeweiss, Andreas ;

Zubel, Angela ;

Groos, Jutta ;

Melezinkova, Helena ;

Awada, Ahmad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) :2586-+

[5] Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab [J].

Basho, Reva K. ;

Gilcrease, Michael ;

Murthy, Rashmi K. ;

Helgason, Thorunn ;

Karp, Daniel D. ;

Meric-Bernstam, Funda ;

Hess, Kenneth R. ;

Herbrich, Shelley M. ;

Valero, Vicente ;

Albarracin, Constance ;

Litton, Jennifer K. ;

Chavez-MacGregor, Mariana ;

Ibrahim, Nuhad K. ;

Murray, James L., III ;

Koenig, Kimberly B. ;

Hong, David ;

Subbiah, Vivek ;

Kurzrock, Razelle ;

Janku, Filip ;

Moulder, Stacy L. .

JAMA ONCOLOGY, 2017, 3 (04) :509-515

[6] Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial [J].

Bernsdorf, Mogens ;

Ingvar, Christian ;

Jorgensen, Leif ;

Tuxen, Malgorzata K. ;

Jakobsen, Erik H. ;

Saetersdal, Anna ;

Kimper-Karl, Marie Louise ;

Kroman, Niels ;

Balslev, Eva ;

Ejlertsen, Bent .

BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (02) :463-470

[7] Prognosis of BRCA-associated breast cancer: a summary of evidence [J].

Bordeleau, L. ;

Panchal, S. ;

Goodwin, P. .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) :13-24

[8] Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients [J].

Botti, Gerardo ;

Collina, Francesca ;

Scognamiglio, Giosue ;

Rao, Federica ;

Peluso, Valentina ;

De Cecio, Rossella ;

Piezzo, Michela ;

Landi, Gabriella ;

De Laurentiis, Michelino ;

Cantile, Monica ;

Di Bonito, Maurizio .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (02)

[9] Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial [J].

Brufsky, Adam ;

Valero, Vicente ;

Tiangco, Beatrice ;

Dakhil, Shaker ;

Brize, Arija ;

Rugo, Hope S. ;

Rivera, Ragene ;

Duenne, Anja ;

Bousfoul, Naima ;

Yardley, Denise A. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) :1067-1075

[10] Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].

Burstein, Matthew D. ;

Tsimelzon, Anna ;

Poage, Graham M. ;

Coyington, Kyle R. ;

Contreras, Alejandro ;

Fuqua, Suzanne A. W. ;

Sayage, Michelle I. ;

Osborne, C. Kent ;

Hilsenbeck, Susan G. ;

Chang, Jenny C. ;

Mills, Gordon B. ;

Lau, Ching C. ;

Brown, Powel H. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698

← 1 2 3 4 5 6 7 8 9 10 →